These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 11948114

  • 1. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.
    Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD.
    Clin Cancer Res; 2002 Apr; 8(4):1061-7. PubMed ID: 11948114
    [Abstract] [Full Text] [Related]

  • 2. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [Abstract] [Full Text] [Related]

  • 3. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ.
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [Abstract] [Full Text] [Related]

  • 4. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    Scandinavian Breast Group Trial 9401Laboratory of Cancer Biology, Institute of Medical Technology, and Department of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland., Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.
    J Clin Oncol; 2006 Jun 01; 24(16):2428-36. PubMed ID: 16682728
    [Abstract] [Full Text] [Related]

  • 5. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
    Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A.
    Cancer Treat Rev; 2009 Dec 01; 35(8):662-7. PubMed ID: 19758759
    [Abstract] [Full Text] [Related]

  • 6. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients.
    Zhu L, Li YF, Chen WG, He JR, Peng CH, Zhu ZG, Li HW.
    Chin Med J (Engl); 2008 Oct 20; 121(20):1965-8. PubMed ID: 19080257
    [Abstract] [Full Text] [Related]

  • 7. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
    Mueller RE, Parkes RK, Andrulis I, O'Malley FP.
    Genes Chromosomes Cancer; 2004 Apr 20; 39(4):288-97. PubMed ID: 14978790
    [Abstract] [Full Text] [Related]

  • 8. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
    Arpino G, Ciocca DR, Weiss H, Allred DC, Daguerre P, Vargas-Roig L, Leuzzi M, Gago F, Elledge R, Mohsin SK.
    Breast Cancer Res Treat; 2005 Jul 20; 92(1):69-75. PubMed ID: 15980993
    [Abstract] [Full Text] [Related]

  • 9. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V, Schiffers J, Kahlert S, Mainka P, Engel J, Kirchner T, Diebold J, Mayr D.
    Diagn Mol Pathol; 2012 Jun 20; 21(2):77-83. PubMed ID: 22555090
    [Abstract] [Full Text] [Related]

  • 10. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
    Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC.
    Clin Cancer Res; 2010 Apr 15; 16(8):2391-401. PubMed ID: 20371687
    [Abstract] [Full Text] [Related]

  • 11. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
    Tanner M, Järvinen P, Isola J.
    Cancer Res; 2001 Jul 15; 61(14):5345-8. PubMed ID: 11454672
    [Abstract] [Full Text] [Related]

  • 12. Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer.
    Arriola E, Moreno A, Varela M, Serra JM, Falo C, Benito E, Escobedo AP.
    Eur J Cancer; 2006 Nov 15; 42(17):2954-60. PubMed ID: 16935488
    [Abstract] [Full Text] [Related]

  • 13. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
    Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy JY, Rouas G, Sotiriou C, Renard N, Richard V, Piccart MJ, Di Leo A.
    Int J Oncol; 2004 Jan 15; 24(1):201-9. PubMed ID: 14654958
    [Abstract] [Full Text] [Related]

  • 14. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A.
    Hum Pathol; 2006 Oct 15; 37(10):1333-43. PubMed ID: 16949920
    [Abstract] [Full Text] [Related]

  • 15. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K, Trojanec R, Kolár Z, Cwiertka K, Cernáková I, Mihál V, Hajdúch M.
    Neoplasma; 2006 Oct 15; 53(5):393-401. PubMed ID: 17013533
    [Abstract] [Full Text] [Related]

  • 16. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG, Lange J, Kett A, Dornhöfer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B.
    Cancer Res; 1999 Jul 01; 59(13):3206-14. PubMed ID: 10397267
    [Abstract] [Full Text] [Related]

  • 17. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS.
    Mod Pathol; 2000 May 01; 13(5):542-7. PubMed ID: 10824926
    [Abstract] [Full Text] [Related]

  • 18. Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis.
    Coss A, Tosetto M, Fox EJ, Sapetto-Rebow B, Gorman S, Kennedy BN, Lloyd AT, Hyland JM, O'Donoghue DP, Sheahan K, Leahy DT, Mulcahy HE, O'Sullivan JN.
    Cancer Lett; 2009 Apr 18; 276(2):228-38. PubMed ID: 19111388
    [Abstract] [Full Text] [Related]

  • 19. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
    Du Y, Zhou Q, Yin W, Zhou L, Di G, Shen Z, Shao Z, Lu J.
    Breast Cancer Res Treat; 2011 Oct 18; 129(3):839-48. PubMed ID: 21809115
    [Abstract] [Full Text] [Related]

  • 20. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
    Tinari N, Lattanzio R, Natoli C, Cianchetti E, Angelucci D, Ricevuto E, Ficorella C, Marchetti P, Alberti S, Piantelli M, Iacobelli S.
    Clin Cancer Res; 2006 Mar 01; 12(5):1501-6. PubMed ID: 16533774
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.